Compare TV & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TV | NVAX |
|---|---|---|
| Founded | 1969 | 1987 |
| Country | Mexico | United States |
| Employees | N/A | 749 |
| Industry | Broadcasting | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.6B |
| IPO Year | N/A | 1996 |
| Metric | TV | NVAX |
|---|---|---|
| Price | $2.84 | $9.93 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 9 |
| Target Price | $4.93 | ★ $11.33 |
| AVG Volume (30 Days) | 1.7M | ★ 4.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | N/A | ★ 309.76 |
| EPS | N/A | ★ 2.58 |
| Revenue | N/A | ★ $1,123,479,000.00 |
| Revenue This Year | $0.03 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.85 |
| Revenue Growth | N/A | ★ 64.69 |
| 52 Week Low | $1.55 | $5.01 |
| 52 Week High | $3.49 | $11.85 |
| Indicator | TV | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 35.81 | 56.94 |
| Support Level | $2.67 | $6.34 |
| Resistance Level | $2.93 | $10.42 |
| Average True Range (ATR) | 0.17 | 0.70 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 31.22 | 43.22 |
Televisa is one of the leading telecommunication firms in Mexico. Its cable arm, Izzi, holds networks that pass 20 million Mexican homes and provide broadband service to nearly 6 million customers. The firm is also one of the largest pay-television providers in Mexico, with 4 million customers. Televisa owns Sky Mexico, the country's only satellite-TV provider, serving about 5 million customers. After merging its traditional media business into Univision, Grupo Televisa owns a 43% stake in combined entity TelevisaUnivision. Grupo Televisa spun off several smaller businesses, including magazine publishing, three of Mexico's professional soccer teams, and Azteca Stadium in February 2024, under the name Ollamani.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.